

EFFECTS OF CONCURRENT RONIDAZOLE AND PROBIOTIC THERAPY IN CATS WITH *TRITRICHOMONAS* FOETUS-ASSOCIATED DIARRHOEA

Stephanie M Lalor, Daniëlle A Gunn-Moore

Royal (Dick) School of Veterinary Studies, Division of Veterinary Clinical Sciences
The University of Edinburgh, Scotland, UK.

This was a prospective double-blinded placebo controlled trial designed to determine if there was a beneficial effect to giving a probiotic in addition to ronidazole for the treatment of *Tritrichomonas foetus*-associated diarrhoea in cats. The probiotic used was Pro-Kolin Enterogenic (PKE) which contains the probiotic *Enterococcus faecium*, several prebiotics, alpha-glucan butyrogenic, and a patented mucopolysaccharide starch.

Tritrichomonas foetus (*T. foetus*) is a protozoal parasite that is a common cause of refractory large bowel diarrhoea in cats in the UK¹. The disease is most commonly seen in purebred, young cats¹. The most sensitive method of detection is PCR², and ronidazole is usually effective in its treatment³. However, ronidazole is not a licensed drug, it can cause serious side effects in cats (such as neurological signs)⁴ and it is thought to be teratogenic.

Probiotics, with or without the addition of antibiotics, have been shown to be useful in the treatment of some gastrointestinal diseases in people⁵, cats⁶, and dogs⁷, and no adverse side effects have been reported. Pro-Kolin Enterogenic (PKE) is a commercially available product which contains the probiotic *Enterococcus faecium*, several prebiotics, alpha-glucan butyrogenic, and a patented mucopolysaccharide starch. Alpha-glucan is a resistant starch and ingestion has been shown to induce pronounced changes in the colonic environment, reducing damage to colonocytes, improving mucosal integrity and reducing colonic and systemic immune reactivity⁸. In addition, mucopolysaccharide starch has been shown to have a protective effect in animals with enteritis induced by indometacin (a model of Crohn's disease), by reducing intestinal and systemic inflammation⁹.

The trial involved using ronidazole at 10-30mg/kg once daily orally for 2 weeks. The cats were also started on either a placebo or probiotic on the same day as ronidazole (classified as day 1) and this was continued for 4 weeks. A total of 26 cats met the inclusion criteria; 13 in group A and 13 in group B. Group A was the placebo and Group B was the probiotic.

All of the cats in the study were pure-bred cats. The mean age of cats in group A was 9.8 months (range 3-28 months) and the mean age in Group B was 10.8 months (range 2-24 months). There was no significant difference between the ages ($P>0.05$). All cats, with the exception of one in Group A had concurrent infections detected by faecal polymerase chain reaction. The duration of follow up was 2-32 weeks, and there was no significant difference between the mean duration of follow-up between the groups ($P>0.05$)

Both groups improved significantly over the course of treatment with regards to faecal scoring and body weight ($P<0.05$). However, cats that received the probiotic were significantly less likely to have a relapse in clinical signs ($P=0.021$). There were 8 relapses in Group A and only 2 relapses in Group B. No side effects were noted in the trial.

References:

- Gunn-Moore DA, McCann TM, Reed N, et al. Prevalence of *Tritrichomonas foetus* infection in cats with diarrhea in the UK. *J Feline Med Surg* 2007;9:214-218.
- Gookin JL, Stebbins ME, Hunt E, et al. Prevalence of and risk factors for feline *Tritrichomonas foetus* and giardia infection. *J Clin Microbiol* 2004;42:2707-2710.
- Gookin JL, Copple CN, Papich MG, et al. Efficacy of ronidazole for treatment of feline *Tritrichomonas foetus* infection. *J Vet Intern Med* 2006;20:536-543.
- Rosado TW, Specht A, Marks SL. Neurotoxicosis in 4 cats receiving ronidazole. *J Vet Intern Med* 2007;21:328-331.
- Armuzzi A, Cremonini F, Bartolozzi F, et al. The effect of oral administration of *Lactobacillus GG* on antibiotic-associated gastrointestinal side-effects during *Helicobacter pylori* eradication therapy. *Aliment Pharmacol Ther* 2001;15:163-169.
- Hart ML, Suchodolski JS, Steiner JM, et al. Open-label trial of a multi-strain synbiotic in cats with chronic diarrhea. *J Feline Med Surg* 14:240-245.
- Sauter SN, Benyacoub J, Allenspach K, et al. Effects of probiotic bacteria in dogs with food responsive diarrhea treated with an elimination diet. *J Anim Physiol Anim Nutr (Berl)* 2006;90:269-277.
- Nofrarias M, Martinez-Puig D, Pujols J, et al. Long-term intake of resistant starch improves colonic mucosal integrity and reduces gut apoptosis and blood immune cells. In: *Nutrition*. United States: 2007:861-870.
- Vergara DP. Study of mps-protect in an enteritis model induced by the administration of indometacin in rat. Internal data, Bioiberica SA.
- Ng SC, Hart AL, Kamm MA, et al. Mechanisms of action of probiotics: recent advances. *Inflamm Bowel Dis* 2009;15:300-3101.
- Bell ET, Gowan RA, Lingard AE, et al. Naturally occurring *Tritrichomonas foetus* infections in Australian cats: 38 cases. *J Feline Med Surg* 2010;12:889-898.
- Gookin JL, Stauffer SH, Dybas D, et al. Documentation of in vivo and in vitro aerobic resistance of feline *Tritrichomonas foetus* isolates to ronidazole. *J Vet Intern Med* 2010;24:1003-1007.




Figure 1: Bar Chart showing the number of cats which had recurrent clinical signs (relapses) and those which had resolution of clinical signs (resolved) during the follow up period ($P=0.021$). The mean follow up period for group A was 19 weeks and Group B was 20 weeks.

Probiotics can have antimicrobial activities through a variety of mechanisms, including the production of bacteriocins/defensins, competitive inhibition with pathogenic bacteria, inhibition of bacterial adherence or translocation, and a reduction in luminal pH.¹⁰

Tritrichomonas foetus primarily affects young, pedigree cats¹¹ as seen in this study. In this study, relapses were common and occurred in 38.5% of cats, (61.5% in Group A and 15.4% in Group B). One previous study used ronidazole at 30 to 50 mg/kg q12h for 14 days, which resulted in resolution of diarrhoea, and no relapses were identified in the 6 month follow up period³. The lower doses in the current study was chosen due to concerns of side effects and previous reports of efficacy with a lower dose^{4,11}. Another reason for an increase in the relapse rate seen in the current study may be the development of resistance to ronidazole, which has been shown in vitro¹².

This study demonstrated that although 10-30mg/kg orally q24hr of ronidazole for 2 weeks for the treatment of *Tritrichomonas foetus*-associated diarrhoea is associated with no side effects and resulted in an improvement in clinical signs, the addition of probiotics decreased the risk of a relapse following the end of treatment. Further studies are warranted to investigate the mechanism by which probiotics reduce the incidence of clinical relapses.

